qs_id,statement_number,statement
QS91,1,People with prostate cancer have a discussion about treatment options and adverse effects with a named nurse specialist.
QS91,2,People with Cambridge Prognostic Group (CPG) 1 localised prostate cancer for whom radical treatment is suitable are offered active surveillance.
QS91,3,"People with Cambridge Prognostic Group (CPG) 2, 3, 4 and 5 localised or locally advanced prostate cancer who are offered non‑surgical radical treatment are offered radical radiotherapy and androgen deprivation therapy in combination."
QS91,4,People with adverse effects of prostate cancer treatment are referred to specialist services.
QS91,5,People with hormone‑relapsed metastatic prostate cancer have their treatment options discussed by the urological cancer multidisciplinary team (MDT).
